Insuman Infusat

Insulin human, the active ingredient in Insuman Infusat, is an insulin presented as a 100 IU/mL solution for injection for subcutaneous use. It treats type 1 diabetes, type 2 diabetes when additional therapy is required, and diabetic ketoacidosis. It is indicated for chronic glycemic control and for acute correction of hyperglycaemia in metabolic emergencies.

GNH USA supplies Insuman Infusat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution and regulatory compliance across multiple markets through a reliable cold‑chain logistics network.

Insuman Infusat (insulin human) is used to manage hyperglycemia in diabetes and related metabolic emergencies, providing essential insulin replacement therapy.

- Type 1 diabetes mellitus: provides basal insulin to achieve and maintain target blood glucose levels, reducing risk of acute hyperglycemic events. - Type 2 diabetes mellitus (when other therapies are insufficient): supplies exogenous insulin to reach individualized glycemic goals, supporting patients who cannot achieve control with oral agents alone. - Diabetic ketoacidosis: delivers rapid insulin to lower plasma glucose, suppress ketone production, and help restore acid‑base balance during this life‑threatening emergency.

Insuman Infusat may cause adverse reactions ranging from mild injection‑site irritation to severe systemic events.

Common Side Effects: - Hypoglycemia: low blood glucose levels, symptoms may include sweating, tremor, confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: gradual increase in body weight associated with insulin therapy. - Lipodystrophy: localized changes in subcutaneous fat at repeated injection sites.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response that can be life‑threatening. - Severe hypoglycemia: profound low glucose requiring immediate assistance. - Hypokalemia: low potassium levels that may occur with rapid glucose shifts.

When using Insuman Infusat, clinicians should consider several precautionary measures to ensure safe and effective therapy.

- Dose adjustment: tailor dose based on blood glucose monitoring and clinical response. - Renal impairment: monitor closely as insulin clearance may be reduced. - Hypoglycemia risk: educate patients on signs and management. - Pregnancy and lactation: use only if benefits outweigh risks. - Drug interactions: review concomitant medications that affect glucose. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Infusat can interact with other medicines, altering its glucose‑lowering effect or masking symptoms.

Major Interactions (Avoid): - Beta‑blockers: may mask signs of hypoglycemia, making detection difficult. - Sulfonylureas or meglitinides: combined use increases risk of severe hypoglycemia. - Glucagon: antagonizes insulin action and may reduce therapeutic effectiveness.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may increase insulin requirements. - Thiazide diuretics: can raise blood glucose levels, necessitating dose adjustment. - Corticosteroids: may diminish insulin efficacy and require higher dosing.